Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:19:48 EDT Sat 10 May 2025
Enter Symbol
or Name
USA
CA



Q:FATE - FATE THERAPEUTICS - https://www.fatetherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FATE - Q0.31.07·1.150.41.04+0.011.01,779.31,8012,7621.04  1.1375  1.035.91  0.661119:44:03May 0215 min RT 2¢

Recent Trades - Last 10 of 2762
Time ETExPriceChangeVolume
19:44:03Q1.100.0710
18:45:03Q1.100.0750
18:07:29Q1.100.072,000
16:08:06Q1.040.0114
16:07:38Q1.03 3
16:05:12Q1.040.011
16:05:09Q1.040.011
16:02:01Q1.040.0113,724
16:01:55Q1.040.011,100
16:01:29Q1.040.01128

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-04-29 09:26U:FATENews ReleaseFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
2025-04-14 08:00U:FATENews ReleaseFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
2025-04-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-03-05 16:01U:FATENews ReleaseFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
2025-03-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2025-02-14 16:01U:FATENews ReleaseFate Therapeutics to Present at Upcoming Investor Conferences
2025-02-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2025-01-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-12-09 16:01U:FATENews ReleaseFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
2024-12-03 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-11-29 13:05U:FATENews ReleaseFate Therapeutics Announces Leadership Transition
2024-11-26 16:01U:FATENews ReleaseFate Therapeutics to Present at Upcoming December Investor Conferences
2024-11-18 08:05U:FATENews ReleaseFate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
2024-11-18 08:00U:FATENews ReleaseFate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
2024-11-12 16:01U:FATENews ReleaseFate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
2024-11-09 13:30U:FATENews ReleaseFate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
2024-11-08 16:01U:FATENews ReleaseFate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
2024-11-04 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 16:01U:FATENews ReleaseFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)